Metabolic volume and lesion glycolysis as measured through 18F-FDG-PET performed better in predicting survival among radioembolization-treated patients with metastatic colorectal cancer than standardized guidelines for uptake, according to a study reported in The Journal of Nuclear Medicine. Patients who exhibited a change in metabolic volume had survival of 92 weeks, compared with 49 weeks, while for those with lesion glycolysis, survival was 91 weeks, compared with 48. Meanwhile, "changes in SUVpeak or SUVmax and RECIST 1.1 criteria did not predict survival," researchers wrote.

Related Summaries